Boston Scientific Corporation $BSX Shares Sold by Ellevest Inc.

Ellevest Inc. trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 6.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 13,729 shares of the medical equipment provider’s stock after selling 979 shares during the period. Ellevest Inc.’s holdings in Boston Scientific were worth $1,475,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. 1248 Management LLC acquired a new stake in shares of Boston Scientific in the first quarter worth approximately $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the first quarter worth approximately $27,000. Sound Income Strategies LLC boosted its stake in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the last quarter. Princeton Global Asset Management LLC acquired a new stake in shares of Boston Scientific in the second quarter worth approximately $32,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Boston Scientific in the second quarter worth approximately $37,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ellen M. Zane sold 9,990 shares of the company’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $101.13, for a total value of $1,010,288.70. Following the completion of the transaction, the director directly owned 27,035 shares in the company, valued at approximately $2,734,049.55. This trade represents a 26.98% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 162,891 shares of company stock worth $16,475,387. Corporate insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on BSX shares. Leerink Partners lifted their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Truist Financial lifted their price target on Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Evercore ISI reaffirmed an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and an average target price of $123.77.

Boston Scientific Stock Up 0.2%

BSX stock opened at $98.79 on Wednesday. The firm has a market cap of $146.38 billion, a PE ratio of 52.83, a PEG ratio of 2.02 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm’s 50 day moving average price is $100.48 and its 200-day moving average price is $102.45. Boston Scientific Corporation has a one year low of $84.13 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the previous year, the company earned $0.63 EPS. The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.